Skip to main content
. 2020 Dec 23;15(12):e0242710. doi: 10.1371/journal.pone.0242710

Fig 3. Trend analysis of percentage per year of PLWH prescribed efavirenz or dolutegravir, respectively, and percentage of PLWH reporting side effects.

Fig 3